GlassScriptPhysician profile
Mark M Kanzawa
NPI 1982617288
$1,156.13
in general payments reported to CMS, 2019-2025
13 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.08 · 2021: $85.58 · 2022: $84.08 · 2023: $175 · 2024: $268 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $242.46 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $197.04 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.99 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $114.01 | 2023-2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $113.09 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $95.67 | 2021-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $51.43 | 2025 | |
| Lundbeck LLC | $51.16 | 2021-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $49.46 | 2022-2025 | Fanapt |
| Indivior INC. | $41.68 | 2023-2024 | Perseris |
| Abbvie INC. | $40.90 | 2023-2024 | |
| Noven Therapeutics, LLC | $19.42 | 2024 | Secuado |
| Ironshore Pharmaceuticals INC. | $16.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kanzawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.